PHASE 1B STUDY OF VENETOCLAX COMBINED WITH BORTEZOMIB AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA

被引：0
|
作者：
Moreau, P. [1 ]
Chanan-Khan, A. [2 ]
Roberts, A. W. [3 ]
Agarwal, A. [4 ]
Facon, T. [5 ]
Kumar, S. [2 ]
Touzeau, C. [1 ]
Diehl, S. [6 ]
Cordero, J. [6 ]
Ross, J. [6 ]
Munasinghe, W. [6 ]
Zhu, M. [6 ]
Salem, A. H. [6 ]
Leverson, J. [6 ]
Maciag, P. [6 ]
Verdugo, M. [6 ]
Harrison, S. J. [7 ]
机构：
[1] CHU Nantes, Hotel Dieu HME, Nantes, France
[2] Mayo Clin, Rochester, MN USA
[3] Royal Melbourne Hosp, Melbourne, Vic, Australia
[4] Univ Arizona, Ctr Canc, Tucson, AZ USA
[5] Hop Huriez, CHRU Lille, Lille, France
[6] AbbVie Inc, N Chicago, IL USA
[7] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia
来源：
HAEMATOLOGICA | 2016年 / 101卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P272
引用
收藏
页码：81 / 82
页数：2
相关论文
共 50 条
  • [21] First Analysis from a Phase 1/2 Study of Venetoclax in Combination with Daratumumab and Dexamethasone, plus /-Bortezomib, in Patients with Relapsed/Refractory Multiple Myeloma
    Bahlis, Nizar
    Baz, Rachid
    Harrison, Simon
    Quach, Hang
    Ho, Shir-Jing
    Vangsted, Annette Juul
    Moreau, Philippe
    Gibbs, Simon
    Salem, Ahmed Hamed
    Ross, Jeremy A.
    Pesko, John
    Westrup, Sally
    Vue, Jenny
    Maciag, Paulo C.
    Bueno, Orlando F.
    Kaufman, Jonathan L.
    BLOOD, 2019, 134
  • [22] Phase 1 open-label study of panobinostat, lenalidomide, bortezomib + dexamethasone in relapsed and relapsed/refractory multiple myeloma
    Jacob P. Laubach
    Sascha A. Tuchman
    Jacalyn M. Rosenblatt
    Constantine S. Mitsiades
    Kathleen Colson
    Kelly Masone
    Diane Warren
    Robert A. Redd
    Dena Grayson
    Paul G. Richardson
    Blood Cancer Journal, 11
  • [23] Phase 2 Study of Venetoclax Plus Carfilzomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma
    Costa, Luciano J.
    Stadtmauer, Edward A.
    Morgan, Gareth
    Monohan, Gregory
    Kovacsovics, Tibor
    Burwick, Nicholas
    Jakubowiak, Andrzej
    Kaufman, Jonathan L.
    Mobasher, Mehrdad
    Freise, Kevin J.
    Ross, Jeremy A.
    Pesko, John
    Munasinghe, Wijith
    Gudipati, Saketh
    Mudd, Sarah
    Bueno, Orlando
    Kumar, Shaji K.
    BLOOD, 2018, 132
  • [24] Ricolinostat plus lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: a multicentre phase 1b trial
    Yee, Andrew J.
    Bensinger, William I.
    Supko, Jeff Rey G.
    Voorhees, Peter M.
    Berdeja, Jesus G.
    Richardson, Paul G.
    Libby, Edward N.
    Wallace, Ellen E.
    Birrer, Nicole E.
    Burke, Jill N.
    Tamang, David L.
    Yang, Min
    Jones, Simon S.
    Wheeler, Catherine A.
    Markelewicz, Robert J.
    Raje, Noopur S.
    LANCET ONCOLOGY, 2016, 17 (11): : 1569 - 1578
  • [25] Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma
    Costa, Luciano J.
    Davies, Faith E.
    Monohan, Gregory P.
    Kovacsovics, Tibor
    Burwick, Nicholas
    Jakubowiak, Andrzej
    Kaufman, Jonathan L.
    Hong, Wan-Jen
    Dail, Monique
    Salem, Ahmed Hamed
    Yang, Xiaoqing
    Masud, Abdullah A.
    Munasinghe, Wijith
    Ross, Jeremy A.
    Bueno, Orlando F.
    Kumar, Shaji K.
    Stadtmauer, Edward A.
    BLOOD ADVANCES, 2021, 5 (19) : 3748 - 3759
  • [26] Final Analysis of a Phase 1b Study of Daratumumab in Combination with Carfilzomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma (RRMM)
    Chari, Ajai
    Lonial, Sagar
    Martinez-Lopez, Joaquin
    Mateos, Maria-Victoria
    Blade, Joan
    Benboubker, Lotfi
    Oriol, Albert
    Otero, Paula Rodriguez
    Pineiro, Luis
    Jakubowiak, Andrzej
    Olyslager, Yunsi
    Wang, Jianping
    Nnane, Ivo
    Ukropec, Jon
    Shreeve, Martin
    Qi, Ming
    Moreau, Philippe
    BLOOD, 2019, 134
  • [27] Weekly carfilzomib, lenalidomide, and dexamethasone (KRd) in relapsed or refractory multiple myeloma (RRMM): A phase 1b study.
    Biran, Noa
    Siegel, David Samuel DiCapua
    Berdeja, Jesus G.
    Raje, Noopur S.
    Cornell, Robert F.
    Alsina, Melissa
    Kovacsovics, Tibor
    Fang, Belle
    Kimball, Amy
    Landgren, Carl Ola
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [28] Updated results from BELLINI, a phase III study of venetoclax or placebo in combination with bortezomib and dexamethasone in relapsed/refractory multiple myeloma.
    Kumar, Shaji
    Harrison, Simon J.
    Cavo, Michele
    de La Rubia, Javier
    Popat, Rakesh
    Gasparetto, Cristina
    Hungria, Vania
    Salwender, Hans
    Suzuki, Kenshi
    Kim, Inho
    Gay, Francesca
    Mikala, Gabor
    Punnoose, Elizabeth
    Hong, Wan-Jen
    Sood, Anjla
    Jalaluddin, Muhammad
    Ross, Jeremy A.
    Pauff, James M.
    Maciag, Paulo Cesar
    Moreau, Philippe
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [29] A Phase II Study of Elotuzumab in Combination with Pomalidomide, Bortezomib, and Dexamethasone in Relapsed and Refractory Multiple Myeloma
    Yee, Andrew J.
    Laubach, Jacob P.
    Campagnaro, Erica L.
    Lipe, Brea C.
    Nadeem, Omar
    Friedman, Robb S.
    Cole, Craig E.
    O'Donnell, Elizabeth K.
    Bianchi, Giada
    Branagan, Andrew R.
    Shapiro, Samantha J.
    Harrington, Cynthia C.
    Burke, Jill N.
    Gammon, Marilyn T.
    Lively, Kathleen J.
    Thorburn, Cassandra A.
    Mann, Mason L.
    Lohr, Jens G.
    Anderson, Kenneth C.
    Richardson, Paul G.
    Raje, Noopur S.
    BLOOD, 2019, 134
  • [30] A phase 2 study of ibrutinib in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma
    Hajek, Roman
    Pour, Ludek
    Ozcan, Muhit
    Sanchez, Jesus Martin
    Sanz, Ramon Garcia
    Anagnostopoulos, Achilles
    Oriol, Albert
    Cascavilla, Nicola
    Terjung, Andreas
    Lee, Yihua
    Briso, Eva M.
    Dobkowska, Edyta
    Hauns, Bernhard
    Spicka, Ivan
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2020, 104 (05) : 435 - 442
12345